CO6400221A2 - Derivados de tidiazoles y oxadiazoles, su preparación y su aplicación en terapia - Google Patents
Derivados de tidiazoles y oxadiazoles, su preparación y su aplicación en terapiaInfo
- Publication number
- CO6400221A2 CO6400221A2 CO11094698A CO11094698A CO6400221A2 CO 6400221 A2 CO6400221 A2 CO 6400221A2 CO 11094698 A CO11094698 A CO 11094698A CO 11094698 A CO11094698 A CO 11094698A CO 6400221 A2 CO6400221 A2 CO 6400221A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapy
- derivatives
- tidiazols
- oxadiazols
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a derivados de tiadiazoles y oxadiazoles inhibidores de la biosíntesis de triglicéridos, a un compuesto de fórmula (I), o una sal de adición de este último a un ácido o una base farmacéuticamente aceptable del compuesto de fórmula (I), composiciones farmacéuticas que lo comprenden para administración oral, sublingual, subcutánea, intramuscular, intravenosa, tópica, local, intratraqueal, intranasal, transdérmica o rectal y sus aplicaciones en terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0900359A FR2941457A1 (fr) | 2009-01-28 | 2009-01-28 | Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique |
FR0904137A FR2949464B1 (fr) | 2009-09-01 | 2009-09-01 | Derives de thiadiazoles et d'oxadiazoles, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6400221A2 true CO6400221A2 (es) | 2012-03-15 |
Family
ID=42261833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11094698A CO6400221A2 (es) | 2009-01-28 | 2011-07-28 | Derivados de tidiazoles y oxadiazoles, su preparación y su aplicación en terapia |
Country Status (26)
Country | Link |
---|---|
US (1) | US8546391B2 (es) |
EP (1) | EP2391611B1 (es) |
JP (1) | JP2012516312A (es) |
KR (1) | KR20110112845A (es) |
CN (1) | CN102365273A (es) |
AR (1) | AR075177A1 (es) |
AU (1) | AU2010209545A1 (es) |
BR (1) | BRPI1007414A2 (es) |
CA (1) | CA2750742A1 (es) |
CL (1) | CL2011001839A1 (es) |
CO (1) | CO6400221A2 (es) |
CR (1) | CR20110403A (es) |
DO (1) | DOP2011000245A (es) |
EA (1) | EA201170983A1 (es) |
EC (1) | ECSP11011224A (es) |
IL (1) | IL214260A0 (es) |
MA (1) | MA33069B1 (es) |
MX (1) | MX2011007991A (es) |
NI (1) | NI201100149A (es) |
NZ (1) | NZ594244A (es) |
PE (1) | PE20120362A1 (es) |
TN (1) | TN2011000353A1 (es) |
TW (1) | TW201031645A (es) |
UY (1) | UY32405A (es) |
WO (1) | WO2010086551A1 (es) |
ZA (1) | ZA201105525B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
CN102557941B (zh) * | 2010-12-07 | 2015-04-22 | 成都睿智化学研究有限公司 | 一种螺环丙基甲酰衍生物的中间体化合物的制备方法 |
US9550793B2 (en) * | 2012-10-03 | 2017-01-24 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
WO2014060381A1 (de) * | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
JP6431538B2 (ja) * | 2013-11-21 | 2018-11-28 | マーケット ユニバーシティー | エストロゲン受容体ベータアイソフォームの選択的アゴニストとしての置換(4’−ヒドロキシフェニル)シクロアルカン化合物およびその使用 |
WO2015106272A1 (en) * | 2014-01-13 | 2015-07-16 | Harki Daniel A | Small molecule inhibitors of apobec3g and apobec3b |
EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
JP6483272B2 (ja) * | 2015-02-17 | 2019-03-13 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | 白色脂肪組織の褐色化を誘導するための化合物および方法 |
CN106278895B (zh) * | 2015-05-15 | 2021-07-09 | Dic株式会社 | 羧酸化合物、其制造方法、使用该化合物的液晶组合物 |
WO2019193540A1 (en) * | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
WO2004004665A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
US20050143384A1 (en) * | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
GB0427328D0 (en) * | 2004-12-14 | 2005-01-19 | Astrazeneca Ab | Chemical compounds |
GB0511851D0 (en) * | 2005-06-11 | 2005-07-20 | Astrazeneca Ab | Chemical compounds |
KR20080015113A (ko) | 2005-06-11 | 2008-02-18 | 아스트라제네카 아베 | Dgat 억제제로서의 옥사디아졸 유도체 |
AU2007236049A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
-
2010
- 2010-01-27 PE PE2011001392A patent/PE20120362A1/es not_active Application Discontinuation
- 2010-01-27 MX MX2011007991A patent/MX2011007991A/es not_active Application Discontinuation
- 2010-01-27 BR BRPI1007414-7A patent/BRPI1007414A2/pt not_active IP Right Cessation
- 2010-01-27 MA MA34128A patent/MA33069B1/fr unknown
- 2010-01-27 EA EA201170983A patent/EA201170983A1/ru unknown
- 2010-01-27 AR ARP100100186A patent/AR075177A1/es not_active Application Discontinuation
- 2010-01-27 WO PCT/FR2010/050124 patent/WO2010086551A1/fr active Application Filing
- 2010-01-27 NZ NZ594244A patent/NZ594244A/xx not_active IP Right Cessation
- 2010-01-27 CA CA2750742A patent/CA2750742A1/fr not_active Abandoned
- 2010-01-27 JP JP2011546921A patent/JP2012516312A/ja not_active Withdrawn
- 2010-01-27 CN CN2010800142290A patent/CN102365273A/zh active Pending
- 2010-01-27 US US13/145,665 patent/US8546391B2/en not_active Expired - Fee Related
- 2010-01-27 KR KR1020117019841A patent/KR20110112845A/ko not_active Application Discontinuation
- 2010-01-27 AU AU2010209545A patent/AU2010209545A1/en not_active Abandoned
- 2010-01-27 TW TW099102288A patent/TW201031645A/zh unknown
- 2010-01-27 EP EP10707597.0A patent/EP2391611B1/fr active Active
- 2010-01-28 UY UY0001032405A patent/UY32405A/es not_active Application Discontinuation
-
2011
- 2011-07-15 TN TN2011000353A patent/TN2011000353A1/fr unknown
- 2011-07-24 IL IL214260A patent/IL214260A0/en unknown
- 2011-07-25 EC EC2011011224A patent/ECSP11011224A/es unknown
- 2011-07-26 CR CR20110403A patent/CR20110403A/es unknown
- 2011-07-27 ZA ZA2011/05525A patent/ZA201105525B/en unknown
- 2011-07-27 NI NI201100149A patent/NI201100149A/es unknown
- 2011-07-28 CO CO11094698A patent/CO6400221A2/es not_active Application Discontinuation
- 2011-07-28 DO DO2011000245A patent/DOP2011000245A/es unknown
- 2011-07-28 CL CL2011001839A patent/CL2011001839A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2011001839A1 (es) | 2012-01-06 |
BRPI1007414A2 (pt) | 2018-03-06 |
IL214260A0 (en) | 2011-09-27 |
US8546391B2 (en) | 2013-10-01 |
UY32405A (es) | 2010-08-31 |
CA2750742A1 (fr) | 2010-08-05 |
AU2010209545A1 (en) | 2011-08-18 |
AR075177A1 (es) | 2011-03-16 |
WO2010086551A1 (fr) | 2010-08-05 |
TN2011000353A1 (fr) | 2013-03-27 |
US20120040984A1 (en) | 2012-02-16 |
JP2012516312A (ja) | 2012-07-19 |
ZA201105525B (en) | 2012-12-27 |
NZ594244A (en) | 2013-07-26 |
EA201170983A1 (ru) | 2012-03-30 |
NI201100149A (es) | 2011-11-01 |
CR20110403A (es) | 2011-09-21 |
MA33069B1 (fr) | 2012-02-01 |
DOP2011000245A (es) | 2011-09-15 |
CN102365273A (zh) | 2012-02-29 |
EP2391611B1 (fr) | 2014-04-30 |
ECSP11011224A (es) | 2011-08-31 |
PE20120362A1 (es) | 2012-05-04 |
MX2011007991A (es) | 2011-11-18 |
TW201031645A (en) | 2010-09-01 |
EP2391611A1 (fr) | 2011-12-07 |
KR20110112845A (ko) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6400221A2 (es) | Derivados de tidiazoles y oxadiazoles, su preparación y su aplicación en terapia | |
UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
UY32455A (es) | Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia | |
NI201200017A (es) | Formulación farmacéutica | |
DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
GEP20125459B (en) | Compounds for inhibiting mitotic progression | |
DOP2011000254A (es) | Compuestos de piridazinona | |
BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
UY32490A (es) | Inhibidores de beta-secretasa | |
BR112012017402A2 (pt) | inibidores de vírus de flaviviridae | |
EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
MD4582B1 (ro) | Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei | |
CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
EA201270540A1 (ru) | Макроциклические ингибиторы интегразы | |
MX2011011094A (es) | Derivados de prolina como inhibidores de catepsina. | |
IN2014CN04530A (es) | ||
TN2009000049A1 (en) | A pyrrolopyrazin as syk-kinase inhibitor | |
MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
MX2009006598A (es) | Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl). | |
MX2009013804A (es) | Inhibidores novedosos de transcriptasa inversa de vih. | |
MX2010005824A (es) | Derivados de aminotiazol. | |
MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
MA33948B1 (fr) | Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. | |
MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
MD20140044A2 (ro) | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |